Scope and Claims Analysis for US Patent 10,799,487 (Telmisartan + Indapamide + Amlodipine Besylate, No Beta-Blocker)

US Patent 10,799,487 is directed to a fixed-dose pharmaceutical composition that combines telmisartan, indapamide, and amlodipine besylate in defined dose ranges, with an explicit negative limitation that the composition is free of a beta-blocker. The asserted claim set also covers specific dose embodiments and methods of treating hypertension with performance/tolerability outcomes framed relative to “full lowest hypertension therapeutic dose” comparator regimens.

Below is a structured analysis of claim scope, likely claim construction pressure points, enforceable coverage boundaries, and the practical patent landscape implications for generics and next-generation combination products.

What does US Patent 10,799,487 claim: telmisartan indapamide amlodipine besylate fixed-dose combination without a beta-blocker?

Core independent claim scope (Claim 1)

Claim 1 recites a pharmaceutical composition with:

Active ingredients
- (a) telmisartan
- (b) indapamide
- (c) amlodipine besylate
Defined dose ranges
- telmisartan: ~16 mg to ~24 mg
- indapamide: ~1 mg to ~1.5 mg
- amlodipine besylate: ~2 mg to ~3 mg
Negative limitation
- composition is “free of a beta-blocker”
No other functional requirements in Claim 1 are provided in the user-provided text (e.g., no specified excipient system, no particle size, no coating language).

What “free of a beta-blocker” does in enforcement

The negative limitation generally drives scope in two ways:

Direct product infringement: A product containing any beta-blocker (even in small amounts) would likely fall outside the claim, depending on how “beta-blocker” is construed (e.g., whether it includes atypical agents, partial agonists, and whether other adrenergic blockers count).
Design-around pressure: A competitor could attempt to include a beta-blocker to avoid literal coverage, but that changes the therapeutic profile and can trigger separate IP.

Practically, this limitation is an “on/off” gate for composition infringement. If the accused product has only telmisartan + indapamide + amlodipine (and no beta-blocker), Claim 1 is structurally hard to avoid.

How narrow are the dose ranges in US 10,799,487 Claim 1 and how much coverage do they give?

Dose band breadth

Claim 1 dose ranges are moderate-to-tight:

Telmisartan (16–24 mg): a 50% span around 20 mg (common clinically).
Indapamide (1–1.5 mg): centered around 1.25 mg.
Amlodipine besylate (2–3 mg): centered around 2.5 mg, which is a very common low-dose fixed combination anchor.

Likely claim construction behavior

Dose-range claims typically invite arguments about:

whether “about” imports a meaningful tolerance beyond the literal band, and
how close an accused dosage must be to the endpoints.

Given the dependent claims specify “about 1.25 mg,” “about 2.5 mg,” and “about 20 mg,” the patent’s likely intended commercial sweet spot is the standard low-dose combination.

Which specific tablets strengths are explicitly covered by dependent claims 2–8?

Dependent claims operationalize Claim 1’s ranges into concrete formulations. As provided:

Claim	Telmisartan	Indapamide	Amlodipine besylate	Coverage type
2	(16–24 mg per Claim 1)	about 1.25 mg	(2–3 mg per Claim 1)	Indapamide-specific
3	(per Claim 1)	(per Claim 1)	about 2.5 mg	Amlodipine-specific
4	about 20 mg	(per Claim 1)	(per Claim 1)	Telmisartan-specific
5	about 20 mg	about 1.25 mg	about 2.5 mg	Triple-anchor strength
6	about 20 mg	about 1.25 mg	(2–3 mg per Claim 1)	Two-actives fixed
7	about 20 mg	(1–1.5 mg per Claim 1)	about 2.5 mg	Two-actives fixed
8	about 20 mg	about 1.25 mg	about 2.5 mg	Triple-anchor strength (explicit)

Enforcement implication: Even if a generic attempts a slightly different telmisartan or amlodipine strength within the ranges, the independent claim still covers the formulation as long as it remains within the “about” ranges and is beta-blocker-free. Dependent claims add evidentiary and bargaining leverage for the most common marketed strength.

Is US 10,799,487 limited to oral solid dosage forms like tablets or capsules?

Form factor dependent claim (Claim 10 and Claim 9)

Claim 9: composition suitable for oral administration.
Claim 10: composition is in the form of pill, tablet, or capsule.

These do not constrain Claim 1 directly in the text you provided, but they establish explicit oral solid coverage paths. If Claim 1 is asserted against a non-oral formulation, Claim 9/10 matter for scope. For a standard fixed-dose hypertension product, Claim 9/10 read as consistent with typical dosage forms.

What does the method-of-treatment coverage cover: outcomes, comparators, and first-line use?

Claims 11–20 shift from composition to method of treating hypertension via administration of the Claim 1 composition. That creates two distinct infringement tracks:

Direct product infringement (composition claims)
Use-based method infringement (method claims), which can be harder to enforce depending on evidence in the relevant jurisdiction and how courts treat medical steps attributable to physicians and patients.

Claim 11: general hypertension treatment

“administering” the Claim 1 composition to a subject with hypertension.

Blood pressure target and delta claims (Claims 12–15)

SBP less than ~140 mmHg (Claim 12)
SBP reduction ≥ ~10 mmHg (Claim 13)
DBP less than ~90 mmHg (Claim 14)
DBP reduction ≥ ~5 mmHg (Claim 15)

These are performance predicates. In practice, they become proof issues:

clinical trial results, labeling claims, and post-market data,
how measurement is standardized (baseline definition, timing of readings, ABPM vs office BP),
whether outcomes are “expected” or “achieved” under typical use.

Comparative superiority claims (Claims 16–17)

SBP reduction is greater than the reduction obtained with the “full lowest hypertension therapeutic dose” of any one of the (a) telmisartan, (b) indapamide, or (c) amlodipine in the combination.

This clause is the most litigation-relevant in your provided text because it is:

relative, not absolute,
and uses a specialized comparator phrase (“full lowest hypertension therapeutic dose”).

That comparator phrase is likely a focal point for claim construction and expert modeling:

What counts as “lowest hypertension therapeutic dose” for each active?
Are these from approved labeling? trials? guideline doses?
Does “full” mean the complete dose of that active without the other two?

Tolerability/side-effect comparative claim (Claim 18)

“greater long term tolerability and reduced risk of side effects” compared with treatment using the full lowest hypertension therapeutic dose of any one of the (a)/(b)/(c) actives.

This is again comparator-based and introduces:

what side-effect endpoints are contemplated,
and what “long term” means (duration threshold is not in the excerpt).

Treatment positioning (Claims 19–20)

initial or first-line treatment of hypertension (Claim 19)
subject has not received any previous hypertension therapy (Claim 20)

These claims increase the likelihood that the patent is tied to a labeling narrative (first-line initiation) and can create method infringement arguments aligned with prescribing patterns.

Where is the infringement hook for generics: composition vs method claims?

Composition claims likely provide cleaner infringement

For a fixed-dose combination product, composition infringement can be straightforward if the product includes:

telmisartan + indapamide + amlodipine besylate at the claimed dose ranges, and
lacks any beta-blocker.

Even if method endpoints are disputed, composition coverage can still drive liability.

Method claims increase complexity in proof

Method claims require linking “administering” conduct to achieving specific BP/tolerability outcomes, especially the comparator-based “greater than” language in Claims 16–18. The evidence set typically includes:

trial data,
product labeling,
and clinician-patient practice patterns.

What are the key claim-scope boundaries an accused product could test?

Beta-blocker presence
- any beta-blocker inclusion could avoid Claim 1 literal scope.
Dose alignment with ranges
- outside telmisartan 16–24 mg, indapamide 1–1.5 mg, or amlodipine 2–3 mg could avoid Claim 1.
A salt form and identity
- amlodipine is specified as “amlodipine besylate.”
- an accused product using a different amlodipine salt could be argued to be outside literal scope (depends on claim interpretation around “amlodipine besylate” specificity).
Method claims depend on comparator definition
- “full lowest hypertension therapeutic dose” is a litigation construction target for Claims 16–18.
Oral solid dosage forms
- if enforcement is only pursued via Claims 9–10, non-tablet forms could be relevant.

How does this patent landscape interact with FDA Orange Book listings and generic entry risk?

Your excerpt does not include the publication number, filing history, assignee, or expiration date, and the question asks for “detailed analysis of the scope and claims and patent landscape.” Under the constraint that only complete, accurate response content can be produced, this section is not populated with Orange Book, patent-family, or listing-specific details.

What can be stated strictly from the claim language:

The patent is a US composition + method patent directed to a specific fixed triple combination.
If the active triple combination appears as an FDA-approved fixed-dose product, this type of patent is typically listed in the Orange Book (if eligible), creating a Paragraph IV and/or section viii nexus for generic planning.
For any generic attempting entry with a telemisartan/indapamide/amlodipine-besylate fixed dose that falls inside the claimed ranges and remains beta-blocker-free, the composition claims create direct entry risk.

What patent estate should you expect around US 10,799,487 based on the claim architecture?

Even without listing numbers, the claim architecture strongly suggests related coverage categories that frequently co-exist in fixed combination portfolios:

Other triple-dose ratio claims
- same actives with different “about” ranges or additional intermediate strengths.
Dosage form and formulation claims
- excipient systems, coatings, stability, particle engineering, and dissolution profiles.
Method-of-use and comparative efficacy claims
- claims keyed to SBP/DBP thresholds and superior reduction versus monotherapy doses.
First-line initiation labeling claims
- “treatment-naïve” or “first-line” framed methods.

For licensing and enforcement strategy, Claim 1’s broad ratio coverage typically sits at the center, while the dependent claims provide claim “landings” on specific commercial strengths.

Key Takeaways

US 10,799,487 protects a fixed-dose telmisartan + indapamide + amlodipine besylate composition with telmisartan 16–24 mg, indapamide 1–1.5 mg, amlodipine besylate 2–3 mg, and a hard negative limitation: beta-blocker-free.
Dependent claims explicitly anchor around telmisartan ~20 mg, indapamide ~1.25 mg, and amlodipine besylate ~2.5 mg (the most enforceable commercial strength).
Method claims add enforceable hooks tied to SBP/DBP thresholds and reductions, plus comparative superiority over monotherapy doses framed as “full lowest hypertension therapeutic dose” for any one component.
The most practical generic design-around levers from the provided claims are: dose range changes, adding a beta-blocker (at the cost of therapeutic and regulatory alignment), or changing the amlodipine salt form.
Composition claims likely provide the cleaner infringement path; method claims add evidentiary and construction complexity due to the comparative comparator language and outcome predicates.

FAQs

Does a fixed-dose product containing telmisartan, indapamide, and amlodipine that includes any beta-blocker avoid US 10,799,487 Claim 1?
If a generic uses amlodipine in a salt form other than besylate, is it outside literal scope of Claim 1?
What does “full lowest hypertension therapeutic dose” likely mean for comparing SBP/DBP reductions in Claims 16–18?
Do Claims 12–15 require clinical trial-level proof of SBP/DBP targets, or can real-world measurements satisfy the predicate?
Is the patent enforceable against a manufacturer for composition alone, or does it also require proof tied to physician administration under Claims 11–20?

References (APA)

United States Patent 10,799,487. (Claims excerpt provided in prompt).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423-002	Jun 5, 2025		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			A METHOD OF TREATING HYPERTENSION	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018213147	⤷ Start Trial
Australia	2019309329	⤷ Start Trial
Australia	2023274064	⤷ Start Trial
Australia	2025201831	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,799,487

Which drugs does patent 10,799,487 protect, and when does it expire?

Summary for Patent: 10,799,487